On June 26th, BC Health Minister Adrian Dix joined BC-CfE Director Dr. Julio Montaner to mark very encouraging progress on the uptake of HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) in BC, since the January 1st launch of the publicly funded program. At the press event, which took place at Jim Deva Plaza in […]
BC Minister of Health announces swift progress on PrEP program Read More »
According to health officials, Panama’s embrace of Treatment as Prevention® (TasP® ) since 2014 has resulted in quicker diagnosis, as well as accelerating the linkage of patients to antiretroviral therapy (ART) clinics. The country’s HIV diagnoses curve has stabilized in recent years and officials expect it will decrease in the coming years. “We have achieved
Today, Panama cites TasP success in reducing HIV morbidity and mortality Read More »
A revolutionary phylogenetic monitoring program developed at the BC Centre for Excellence in HIV/AIDS (BC-CfE) demonstrates how HIV is spreading across five provinces in Canada. This first-of-its-kind system identifies HIV transmission outbreaks, or “clusters” (groups of recent, related, HIV infections) in near real-time. “HIV does not stop at jurisdictional boundaries. Yet time and time again,
Phylogenetics: The future of the fight against HIV/AIDS and other targeted diseases Read More »
British Columbians, including men and transwomen who have sex with men, people who inject drugs, and people who have sex with individuals living with HIV, can now access free medication to protect against HIV. As of January 1st, the province of British Columbia is covering the cost of pre-exposure prophylaxis treatment (PrEP), recommended by the
BC aims to reduce new cases of HIV with expanded PrEP Read More »
BC leads the way nationally In 1996, BC was the epicenter of the HIV/AIDS crisis in Canada, with the province diagnosing up to 800 people a year at the height of the crisis. Being in the ‘eye of the storm’ forced the province and researchers to address the disease with an innovative spirit and ground-breaking
PEP: Start early, follow up and start a conversation Dr. Marianne Harris, Clinical Research Advisor with the BC Centre for Excellence in HIV/AIDS (BC-CfE), provided an overview of the new BC-CfE PEP (post-exposure prophylaxis) guidelines. Dr. Harris emphasized the safety and tolerability of the PEP regimen will be improved with the use of raltegravir and
Cancer, cardiovascular disease, new PEP guidelines and more: The Fall ARV Update Read More »
Diabetes Canada announced it is adapting the made-in-BC Treatment as Prevention (TasP) strategy to diabetes to make over 6 million Canadians living with pre-diabetes, and diabetes, aware of their status. The epidemic of diabetes and prediabetes affects over 11 million Canadians and can cause blindness, kidney failure, heart attack, stroke and lower limb amputation. Diabetes
Treatment as Prevention model (TasP) and 90-90-90 Target adopted by Diabetes Canada Read More »
The 2017 Spring HIV/Antiretroviral update featured a diverse roster of leading health professionals to discuss the latest numbers from the front lines of the opioid epidemic, advances in Hepatitis C screening and progress in meeting 90-90-90 HIV/AIDS targets around the world. ADDICTION Dr. Patricia Daly characterized the current state of the opioid crisis in Vancouver
In recognition of the BC Centre for Excellence in HIV/AIDS’ (BC-CfE) 25 years of leadership in the battle against HIV/AIDS Dr. Julio Montaner was in Ottawa on May 16th, 2017 to accept the CIHR Gold Leaf Prize for Impact on behalf of the staff of the BC-CfE. The CIHR Gold Leaf Prize for Impact is
Welcoming a new government that embraces evidence-based science has been a breath of fresh air for researchers across the country after a decade of silence from the Canadian government. This is in stark contrast to the previous Conservative government who fought Insite all the way to the Supreme Court of Canada and, subsequently, passed Bill
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
